SUMO1 and SERCA2a Function

SUMO1 和 SERCA2a 功能

基本信息

项目摘要

DESCRIPTION (provided by applicant):The incidence of congestive heart failure continues to increase in the United States despite significant advances in pharmacological therapy and novel devices. For this reason, there is an urgent need for novel therapies to treat heart failure. With a better understanding of the molecular mechanisms involved in the pathogenesis of heart failure, new targets are emerging. A key abnormality in heart failure is defective handling of calcium ions which has been shown to be related to abnormal sarcoplasmic reticulum (SR) function in cardiac myocytes. Reduced expression and activity of SERCA2a have been shown in multiple animal models of heart failure and in cardiomyocytes isolated from failing hearts explanted from patients undergoing transplantation. Restoring SERCA2a expression is associated with improved inotropy and lusitropy of isolated cardiomyocytes and with improved cardiac function in experimental models of heart failure. More recently, our group carried out a First-in-Man randomized gene therapy trial, using adeno-associated type 1vector carrying SERCA2a. In this trial, we found that AAV1.SERCA2a delivered to patients with advanced heart failure led to an improvement in the overall clinical status of patients with systolic heart failur, further highlighting the potential importance of SERCA2a as a therapeutic target in this condition. Our previous work, which led to the initiation of the clinical trials, was based on the premise that changes in the total protein expression of SERCA2a was critical in the calcium cycling abnormalities observed in heart failure. More recently, we found that the levels and activity of SERCA2a are modulated in parallel with the levels of a specific cytoplasmic protein SUMO1 (small ubiquitin-like modifier type 1). SUMOylation has been found to be involved in many cellular processes such as protein transport, gene transcription and DNA replication and repair. We found that SERCA2a and SUMO1 levels were both reduced in models of heart failure and in failing human myocardium. We showed that increasing SUMO1 levels led to improved hemodynamic performance and reduced mortality in a murine model of HF. We now propose to further characterize the molecular mechanisms of SUMO1 in regulating SERCA2a function and to evaluate the multiple pathways regulating SUMOylation of SERCA2a.
描述(由申请人提供):尽管药物治疗和新型器械取得了重大进展,但美国充血性心力衰竭的发病率仍在持续增加。因此,迫切需要新的治疗方法来治疗心力衰竭。 随着对心力衰竭发病机制的深入了解,新的靶点不断涌现。 心力衰竭的一个关键异常是钙离子处理缺陷,已显示其与心肌细胞中异常肌浆网(SR)功能相关。SERCA2a的表达和活性降低已在心力衰竭的多种动物模型和从经历移植的患者的衰竭心脏分离的心肌细胞中显示。在心力衰竭实验模型中,恢复SERCA2a表达与分离的心肌细胞的变力性和收缩性改善以及心脏功能改善相关。最近,我们的小组进行了首次在人随机基因治疗试验,使用腺相关1型载体携带SERCA2a。在这项试验中,我们发现向患有晚期心力衰竭的患者递送AAV1.SERCA2a导致患有收缩性心力衰竭的患者的总体临床状态的改善,进一步突出了SERCA2a作为这种情况下的治疗靶点的潜在重要性。我们之前的工作,导致了临床试验的开始,是基于 这一前提是SERCA2a的总蛋白表达的变化在心力衰竭中观察到的钙循环异常中是关键的。最近,我们发现SERCA2a的水平和活性与特定细胞质蛋白SUMO 1(小泛素样修饰物1型)的水平平行调节。SUMO化参与蛋白质转运、基因转录、DNA复制和修复等多种细胞过程。我们发现SERCA2a和SUMO 1水平在心力衰竭模型和衰竭的人类心肌中均降低。 我们发现,在HF小鼠模型中,增加SUMO 1水平可改善血流动力学性能并降低死亡率。 我们现在建议进一步表征SUMO 1在调节SERCA 2a功能中的分子机制,并评估调节SERCA 2a SUMO化的多种途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roger J. Hajjar其他文献

Structure-Based Design of Phospholamban Mutants for Gene Therapy
  • DOI:
    10.1016/j.bpj.2009.12.4188
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Simon J. Gruber;Kim N. Ha;Elizabeth L. Lockamy;Razvan L. Cornea;Roger J. Hajjar;Gianluigi Veglia;David D. Thomas
  • 通讯作者:
    David D. Thomas
1042. Tracking and Gene Expression Profile of Bone Marrow Mesenchymal Stem Cells Injected into Pig Myocardium by Magnetic Resonance Imaging and Laser-Capture Microdissection
  • DOI:
    10.1016/j.ymthe.2006.08.1138
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elie R. Chemaly;Irina Pomerantseva;Ryuichi Yoneyama;Djamel Lebeche;Davide Gianni;Kozo Hoshino;Yoshiaki Kawase;Federica del Monte;Roger J. Hajjar
  • 通讯作者:
    Roger J. Hajjar
AAV delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine
具有机械支持的腺相关病毒递送策略用于猪的安全有效心脏基因转移
  • DOI:
    10.1038/s41467-024-54635-x
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Renata Mazurek;Serena Tharakan;Spyros A. Mavropoulos;Deanndria T. Singleton;Olympia Bikou;Tomoki Sakata;Taro Kariya;Kelly Yamada;Erik Kohlbrenner;Lifan Liang;Anjali J. Ravichandran;Shin Watanabe;Roger J. Hajjar;Kiyotake Ishikawa
  • 通讯作者:
    Kiyotake Ishikawa
Therapeutic Targeted Delivery of AAV9 Sh BNIP3 Reverses Cardiac Remodeling and Improves Diastolic and Systolic Function in a Rat Model of Pressure Overload Induced Heart Failure
  • DOI:
    10.1016/j.cardfail.2012.06.106
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Antoine H. Chaanine;Ronald E. Gordon;Ludovic Benard;Erik Kohlbrenner;Roger J. Hajjar
  • 通讯作者:
    Roger J. Hajjar
Inhibition of miR-25 ameliorates cardiac and skeletal muscle dysfunction in aged emmdx/utrn/em haploinsufficient (+/−) mice
miR-25的抑制可改善老年EMMDX/UTRN/EM单倍弹性(+/-)小鼠的心脏和骨骼肌功能障碍
  • DOI:
    10.1016/j.omtn.2024.102174
  • 发表时间:
    2024-06-11
  • 期刊:
  • 影响因子:
    6.100
  • 作者:
    Sacha V. Kepreotis;Jae Gyun Oh;Mina Park;Jimeen Yoo;Cholong Lee;Mark Mercola;Roger J. Hajjar;Dongtak Jeong
  • 通讯作者:
    Dongtak Jeong

Roger J. Hajjar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roger J. Hajjar', 18)}}的其他基金

Small Molecule Therapy for the Treatment of Heart Failure
治疗心力衰竭的小分子疗法
  • 批准号:
    9335758
  • 财政年份:
    2017
  • 资助金额:
    $ 42.38万
  • 项目类别:
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
抗 AAV 抗体是心脏 AAV 基因治疗的障碍
  • 批准号:
    9281067
  • 财政年份:
    2016
  • 资助金额:
    $ 42.38万
  • 项目类别:
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
抗 AAV 抗体是心脏 AAV 基因治疗的障碍
  • 批准号:
    9176405
  • 财政年份:
    2016
  • 资助金额:
    $ 42.38万
  • 项目类别:
Role of miR25 in Heart Failure
miR25 在心力衰竭中的作用
  • 批准号:
    9249966
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
Role of miR25 in Heart Failure
miR25 在心力衰竭中的作用
  • 批准号:
    8914275
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MR
治疗心室和瓣膜:MR 缺血性左室重塑的新协同作用
  • 批准号:
    9195751
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
Calcium Pump Activators for Heart Failure Therapy
用于心力衰竭治疗的钙泵激活剂
  • 批准号:
    9268662
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
Calcium Pump Activators for Heart Failure Therapy
用于心力衰竭治疗的钙泵激活剂
  • 批准号:
    9096874
  • 财政年份:
    2015
  • 资助金额:
    $ 42.38万
  • 项目类别:
SUMO1 and SERCA2a Function
SUMO1 和 SERCA2a 功能
  • 批准号:
    8725733
  • 财政年份:
    2013
  • 资助金额:
    $ 42.38万
  • 项目类别:
SUMO1 and SERCA2a Function
SUMO1 和 SERCA2a 功能
  • 批准号:
    8594897
  • 财政年份:
    2013
  • 资助金额:
    $ 42.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了